{"disease":{"id":"familial-amyloidosis","name":"familial amyloidosis"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03190577","title":"Assessment of the Prevalence of TTR Amyloid Neuropathy in a Population of Patients With Neuropathy of Unknown Aetiology","phase":"NA","overall_status":"COMPLETED","enrollment_count":400,"lead_sponsor_name":"Nantes University Hospital","has_results":false},{"nct_id":"NCT01737398","title":"Efficacy and Safety of Inotersen in Familial Amyloid Polyneuropathy","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":173,"lead_sponsor_name":"Ionis Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT02175004","title":"Extension Study Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Familial Amyloid Polyneuropathy (FAP)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":135,"lead_sponsor_name":"Ionis Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT04601051","title":"Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2001 in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN) and Patients With Transthyretin Amyloidosis-Related Cardiomyopathy (ATTR-CM)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":72,"lead_sponsor_name":"Intellia Therapeutics","has_results":false},{"nct_id":"NCT03431896","title":"Monitoring of Early Disease Progression in Hereditary Transthyretin Amyloidosis","phase":"","overall_status":"COMPLETED","enrollment_count":37,"lead_sponsor_name":"The Cleveland Clinic","has_results":false},{"nct_id":"NCT03862807","title":"Patisiran in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) Disease Progression Post-Liver Transplant","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":true},{"nct_id":"NCT01604122","title":"Burden of Disease Study In Patients With Transthyretin Familial Amyloidosis Polyneuropathy (TTR-FAP) orTransthyretin Cardiomyopathy (TTR-CM) And Caregivers","phase":"","overall_status":"COMPLETED","enrollment_count":1,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT02939820","title":"Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR)","phase":"","overall_status":"APPROVED_FOR_MARKETING","enrollment_count":null,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":false}],"total":8},"guidelines":[],"source":"Drug Landscape verified database"}